Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Diabetes, Obesity & Metabolism
|
July 18, 2025
Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1
Jamy Ard, Clare J Lee, Kimberly Gudzune, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 4, 2016
Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
Irene Hadjiyianni, Urvi Desai, Shuichi Suzuki, et al.
Clinical Obesity
|
January 12, 2025
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
Deborah B Horn, Scott Kahan, Rachel L Batterham, et al.
Current Medical Research and Opinion
|
December 26, 2015
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US
Magaly Perez-Nieves, Samaneh Kabul, Urvi Desai, et al.
Obesity Pillars
|
February 5, 2026
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
Jaime P Almandoz, Octavia Pickett-Blakely, Colleen Tewksbury, et al.
Current Medical Research and Opinion
|
June 13, 2017
Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey
Magaly Perez-Nieves, Jasmina I Ivanova, Irene Hadjiyianni, et al.
Cancer
|
November 8, 2014
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer
Robert C Doebele, David Spigel, Mustapha Tehfe, et al.
Journal of Endocrinological Investigation
|
April 19, 2026
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5
Rodolfo J Galindo, Louis J Aronne, Deborah B Horn, et al.
Diabetes, Obesity & Metabolism
|
March 8, 2026
Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks
Hiddo J L Heerspink, Daniel H van Raalte, Katherine Tuttle, et al.
Journal of Diabetes and Its Complications
|
February 3, 2019
Identifying solutions to psychological insulin resistance: An international study
William H Polonsky, Lawrence Fisher, Danielle Hessler, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Diabetes, Obesity & Metabolism
|
July 18, 2025
Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1
Jamy Ard, Clare J Lee, Kimberly Gudzune, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
December 4, 2016
Basal Insulin Persistence, Associated Factors, and Outcomes After Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan
Irene Hadjiyianni, Urvi Desai, Shuichi Suzuki, et al.
Clinical Obesity
|
January 12, 2025
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
Deborah B Horn, Scott Kahan, Rachel L Batterham, et al.
Current Medical Research and Opinion
|
December 26, 2015
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US
Magaly Perez-Nieves, Samaneh Kabul, Urvi Desai, et al.
Obesity Pillars
|
February 5, 2026
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
Jaime P Almandoz, Octavia Pickett-Blakely, Colleen Tewksbury, et al.
Current Medical Research and Opinion
|
June 13, 2017
Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey
Magaly Perez-Nieves, Jasmina I Ivanova, Irene Hadjiyianni, et al.
Cancer
|
November 8, 2014
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer
Robert C Doebele, David Spigel, Mustapha Tehfe, et al.
Journal of Endocrinological Investigation
|
April 19, 2026
Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5
Rodolfo J Galindo, Louis J Aronne, Deborah B Horn, et al.
Diabetes, Obesity & Metabolism
|
March 8, 2026
Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT-1 Over 176 Weeks
Hiddo J L Heerspink, Daniel H van Raalte, Katherine Tuttle, et al.
Journal of Diabetes and Its Complications
|
February 3, 2019
Identifying solutions to psychological insulin resistance: An international study
William H Polonsky, Lawrence Fisher, Danielle Hessler, et al.
Page
of 5